Remifentanil Hydrochloride

Описание

Ultiva was launched in Germany and the US for use in general anesthesia and immediate post-operative pain management. This compound can be prepared via the Michael addition of a 4,4-disubstituted piperidine to methyl acrylate. It behaves as a specific μ-opiod agonist that is about 30 times more potent than its chemical relative alfentanil. While its pharmacodynamic properties are similar to other μ agonists, remifentanil has unique pharmacokinetic properties. It has a rapid onset (1.6 min) and a rapid offset (5.4 min) independent of duration of administration. This has been attributed to its rapid catabolism by general esterases to the corresponding acrylic acid derivative. The metabolite has 0.01 to 0.0005 times the activity of remifentanil and is excreted via the kidneys (80% recovery).

Химические свойства

White Solid

Использование

Labelled synthetic mu-opioid agonist. This is a controlled substance (opiate)

Фармакокине?тика

Remifentanil is much like alfentanil in its pharmacodynamic effects. It is a selective μ opioid agonist with 15 to 20 times greater potency than alfentanil. Remifentanil has an onset of action of 1 to 3 minutes when given intravenously. Its unique property is its rapid offset of action, which is independent of the duration of administration of the compound. Thus, it is very useful for titration of antinociceptive effect, followed by a rapid and predictable recovery time of 3 to 5 minutes. The short duration of action is a result of the ester group, which has been rationally designed into the substituent on the piperidine nitrogen. This ester group is rapidly hydrolyzed to the inactive carboxylic acid by serum and tissue esterases, making the drug's duration of action essentially independent of the liver or renal function of the patient. Remifentanil is used extensively for analgesia associated with general anesthesia procedures. It often is used in combination with injectable general anesthetic agents, such as midazolam or propofol.